Key Trends Shaping the Future In Vitro Diagnostic (IVD) In Cardiology And Neurology Market From 2025-2034: Advancing Diagnostics Through Innovations In AI-Enabled Early Disease Detection

What Is the Estimated Market Size and Growth Rate for the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
The market size for in vitro diagnostic (IVD) in cardiology and neurology has been experiencing robust growth in recent years. The market will surge from $15.84 billion in 2024 to $17.27 billion in 2025, progressing at a compound annual growth rate (CAGR) of 9.0%. Factors influencing this growth during the historic period include an increase in age-related cardiovascular and neurological disorders, a growing aged population, a heightened emphasis on preventive healthcare and early disease detection, a mounting burden of cardiovascular diseases (CVDs) and neurological disorders like stroke and Alzheimer's disease, amplified investments in healthcare infrastructure, and the presence of supportive regulatory frameworks that govern the approval and reimbursement of diagnostic tests.

The market size for in vitro diagnostic (IVD) in both cardiology and neurology is set to witness robust expansion in the coming years, expecting it to scale up to $24.07 billion by 2029 with a compound annual growth rate (CAGR) of 8.7%. This projected growth over the forecast period can be linked to factors like the move towards personalised medicine within the fields of cardiology and neurology, the burgeoning demand for quick and on-site testing solutions, the proliferation of telemedicine and remote consultation offerings, and the increase in research endeavours. Key trends over this forecast period include the rise of liquid biopsy technology, advancements in the field of nanotechnology, increasing adoption of remote monitoring devices such as implantable cardiac monitors and brain-computer interfaces, application of multiplex biomarker panels, the breakthroughs in medical imaging techniques including MRI, CT, and PET scans, and the creation of companion diagnostics for drugs related to cardiovascular and neurological conditions.

What Is Driving the Growth Trajectory of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
The projected growth of the in vitro diagnostic (IVD) in cardiology and neurology market is likely to be propelled by the continuing rise of personalized medicine. Essentially, this form of healthcare practice focuses on tailoring medical decisions, interventions, treatments, and norms to the unique characteristics of each patient. The growth of personalized medicine is being driven by advances in genomics, a better understanding of the ways diseases work, the demands of patients for bespoke treatments, and the backing of regulatory bodies, among other things. In vitro diagnostic (IVD) tests in the fields of cardiology and neurology underpin personalized medicine, offering essential data about a particular individual's genetic makeup and state of health, which aids in devising a customised and effective treatment plan with minimized potential risks. To illustrate, the Personalized Medicine Coalition, a professional membership body in the US, revealed that in 2022, 12 new personalized medicines were approved, comprising around 34% of all new therapies approved, showing a noteworthy increase compared to prior years. Consequently, the surge in the quantity of personalized medicines contributes to the expansion of the in vitro diagnostic (IVD) in cardiology and neurology market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

Who Are the Dominant Companies Influencing In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Trends?
Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

How Is the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Evolving?
Leading firms in the cardiology and neurology in vitro diagnostic (IVD) market are formulating Artificial Intelligence (AI) capable integrated epigenetic systems for the early identification and risk evaluation of diseases. These AI-furnished integrated epigenetic systems employ machine-learning models and sophisticated biomarker analysis methods to boost precision and sensitivity in diagnosing and surveilling cardiovascular illnesses, targeting key factors that facilitate disease escalation. For example, in February 2023, a biotechnology firm based in the US known as Cardio Diagnostics Holdings Inc. introduced PrecisionCHD, a blood test driven by AI, crafted for the early diagnosis of coronary heart disease (CHD). Through the utilization of the corporation's combined genetic and epigenetic engine, this test gauges risk levels associated with CHD and aims to thwart and identify the most prevalent form of cardiovascular ailment. This new product unifies genetic and epigenetic biomarkers with machine-learning formulas, providing over 75% sensitivity for both genders. It ties a patient's biomarker profile to changeable risk elements, significant contributors to CHD, such as smoking, diabetes, hypertension, and elevated cholesterol. PrecisionCHD serves as a non-invasive substitute for exercise stress tests or angiograms, permitting blood samples to be taken in a physician's office or at a patient's residence.

What Are the Different Segmentations in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented -

1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:
1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices
2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables
3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Which Region Is at the Forefront of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Global Market Report?

- Market Size Analysis: Analyze the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall In Vitro Diagnostic (IVD) In Cardiology And Neurology Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.